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Objectives This study sought to develop a practical risk score to predict the risk of stent thrombo-
sis (ST) after percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS).
Background ST is a rare, yet feared complication after PCI with stent implantation. A risk score for
ST after PCI in ACS can be a helpful tool to personalize risk assessment.
Methods This study represents a patient-level pooled analysis of 6,139 patients undergoing PCI
with stent implantation for ACS in the HORIZONS-AMI (Harmonizing Outcomes With Revasculariza-
tion and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Inter-
vention Triage Strategy) trials who were randomized to treatment with bivalirudin versus heparin
plus a glycoprotein IIb/IIIa inhibitor. The cohort was randomly divided into a risk score development
cohort (n  4,093) and a validation cohort (n  2,046). Cox regression methods were used to
identify clinical, angiographic, and procedural characteristics associated with Academic Research
Consortium–deﬁned deﬁnite/probable ST at 1 year. Each covariate in this model was assigned
an integer score based on the regression coefﬁcients.
Results Variables included in the risk score were type of ACS (ST-segment elevation myocardial in-
farction, non-ST-segment elevation ACS with ST deviation, or non–ST-segment elevation ACS with-
out ST changes), current smoking, insulin-dependent diabetes mellitus, prior PCI, baseline platelet
count, absence of early (pre-PCI) anticoagulant therapy, aneurysmal/ulcerated lesion, baseline TIMI
(Thrombolysis In Myocardial Infarction) ﬂow grade 0/1, ﬁnal TIMI ﬂow grade 3, and number of
treated vessels. Risk scores 1 to 6 were considered low risk, 7 to 9 intermediate risk, and 10 or
greater high risk for ST. Rates of ST at 1 year in low-, intermediate-, and high-risk categories were
1.36%, 3.06%, and 9.18%, respectively, in the development cohort (p for trend 0.001), and 1.65%,
2.77%, and 6.45% in the validation cohort (p for trend  0.006). The C-statistic for this risk score
was over 0.65 in both cohorts.
Conclusions The individual risk of ST can be predicted using a simple risk score based on clinical, an-
giographic, and procedural variables. (Harmonizing Outcomes With Revascularization and Stents in Acute
Myocardial Infarction [HORIZONS-AMI]; NCT00433966) (Comparison of Angiomax Versus Heparin in Acute
Coronary Syndromes [ACUITY]; NCT00093158) (J Am Coll Cardiol Intv 2012;5:1097–105) © 2012 by the
American College of Cardiology Foundation
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1098Stent thrombosis (ST) is a rare, yet feared complication
after percutaneous coronary intervention (PCI) that is
associated with high rates of morbidity and mortality
reported by several randomized clinical trials and regis-
See page 1106
tries (1–6). A large number of patient-related, lesion-
related, procedural, and post-procedural factors have been
associated with ST (1–4,6,7). Stenting in prothrombotic
conditions in patients with acute coronary syndromes
(ACS) is strongly associated with the occurrence of ST
(7–9). However, due to the rarity of ST events, systematic
ST risk assessment has not been realized at the individual
patient level. A risk score for ST after PCI in ACS can be
a helpful tool to personalize risk assessment.
In the present study, we aimed to develop and validate a
practical risk score for ST based on a pooled analysis of
patients undergoing PCI with stent implantation in 2
prospective randomized clinical
trials of patients with ACS
(10,11).
Methods
This study represents a pooled anal-
ysis of patients undergoing PCI
with stent implantation in 2 large
randomized clinical trials of bivali-
rudin versus heparin plus a glyco-
protein IIb/IIIa inhibitor (GPI):
The HORIZONS-AMI (Harmo-
nizing Outcomes With Revascular-
ization and Stents in Acute Myo-
cardial Infarction) trial of patients
with ST-segment elevation myocardial infarction (STEMI); and
the ACUITY (Acute Catheterization and Urgent Intervention
Triage Strategy) trial of patients with unstable angina or non-
STEMI (10,11).
The design and primary outcomes of these trials have
been described in detail previously (11,12). Briefly, in
HORIZONS-AMI, 3,602 patients admitted with STEMI
presenting within 12 h after symptom onset were directed to
Carolina; Department of Cardiology, Auckland City Hospital, Auckland, New
ealand; and the ¶Department of Cardiology, Columbia University Medical Center,
ew York, New York. The HORIZONS-AMI trial was supported by the Cardio-
ascular Research Foundation, with grant support from Boston Scientific and The
edicines Company. Dr. Dangas has received speaker honoraria from AstraZeneca,
ristol-Myers Squibb, The Medicines Company, sanofi-aventis, and Abbott Vascu-
ar. Dr. Mehran has received a research grant from sanofi-aventis and honoraria from
he Medicines Company, Abbott Vascular, sanofi-aventis, Bristol-Myers Squibb,
ordis, and AstraZeneca. Dr. Ohman has received research grants from Daiichi
ankyo, Eli Lilly and Company, and Maquet; and has received consulting fees from
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
GPI  glycoprotein IIb/IIIa
inhibitor
NSTE-ACS  non–ST-
segment elevation acute
coronary syndrome
PCI  percutaneous
coronary intervention
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarctionoche, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Liposcience,
erck, Pozen Inc., sanofi-aventis, The Medicines Company, Gilead Sciences, and atherapy with primary angioplasty and were randomized
(1:1) to receive either bivalirudin monotherapy (plus bailout
GPI) or unfractionated heparin plus a GPI before PCI.
Following angiography, 3,006 patients were randomized
(3:1) to Taxus Express2 (Boston Scientific, Natick, Massa-
chusetts) paclitaxel-eluting stents or otherwise identical
metallic stents (Boston Scientific). Aspirin and clopidogrel
(either 300 or 600 mg, at the discretion of the investigator)
or ticlopidine (500 mg in the case of allergy to clopidogrel)
were administered before catheterization.
In ACUITY, eligible patients with unstable angina or
non-STEMI were randomly assigned to treatment with
bivalirudin, versus bivalirudin plus a GPI, versus heparin
(either unfractionated or low molecular weight) plus a GPI
before performance of coronary angiography. All patients
received aspirin, and timing and dosing of clopidogrel was
left to the discretion of investigators and treating physicians.
Clinical follow-up was prespecified at 30 days, 6 months,
and 1 year in both trials. Extended follow-up of up to 3
years was only available in the HORIZONS-AMI trial.
The Academic Research Consortium definite or probable
ST criteria were used (13), and all ST events were adjudi-
cated using source documents by the independent clinical
event committees of the 2 trials. In both trials, angiographic
analysis was performed by an independent core laboratory
using validated methods.
Risk score development. We randomly divided the pooled
ataset in a 2:1 fashion into a development cohort and a
alidation cohort and considered the 1-year follow-up for
he primary analysis because this was the longest common
ollow-up period for both datasets. Univariate and multi-
ariate analyses for prediction of ST have previously been
erformed in both individual trials (14). A Cox proportional
azards model was used to calculate hazard ratios of clinical,
ngiographic, and procedural variables. Models were built
sing a stepwise variable selection procedure; a value of p 
.05 was set as the level of significance for including
ariables in the model. To prevent overfitting, we included
ovariates that were independent predictors of ST in the
ndividual trials in the model (14). Slight modifications were
ade to accommodate differences between the study data-
ases. 1) ST-segment deviation was classified as STEMI,
on-STEMI with ST-segment deviation 1 mm, or ACS
ebMD. Dr. White has received research grants from sanofi-aventis, Eli Lilly and
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1099without ST-segment deviation. 2) Pre-randomization
administration of antithrombotic medication was associ-
ated with ST in HORIZONS-AMI, and was generalized
to early (pre-PCI) anticoagulant therapy in both trials.
3) Angiographic ulceration (according to the criteria for
complex morphology as proposed by Ambrose et al. [15])
and aneurysm were independent predictors of ST in
HORIZONS-AMI and were generalized to ulceration or
aneurysm, instead of to 2 separate variables. The remaining
variables included were baseline platelet count, current
smoking, insulin-treated diabetes mellitus, prior PCI, num-
ber of treated vessels, baseline TIMI (Thrombolysis In
Myocardial Infarction) flow grade 0/1, and final TIMI flow
grade 3. Use of drug-eluting stents compared with bare-
etal stents was not associated with ST. Each covariate in
his model was assigned an integer score based on the regres-
ion coefficients. Integer scores were subsequently summed to
ive the risk score for each patient. The 1-year rate of ST
ithin each score category was derived per integer score and
hen per low-, intermediate-, or high-risk classification. Addi-
ionally, separate models were created for early (0 to 30 days)
efinite/probable ST and late (1 month to 1 year) ST using the
forementioned methodology. A significant p value for trend
as considered at the0.05 level. Overall model performance
was assessed with the C-statistic.
Score validation. To test the validity of these findings, we
investigated the correlation of the derived risk score with the
ST rate observed in the validation cohort. The rates of ST
per risk score category were derived and compared for trend.
Overall model performance was assessed by the C-statistic.
A secondary analysis was performed with inclusion of the
extended follow-up data of HORIZONS-AMI trial (be-
yond 1- and up to 3-year follow-up) in the validation
dataset to provide information on prediction of very late ST.
Results
A total of 2,986 patients who received stent implantation
Table 1. Rates of Definite Probable ST in Patients From the Individual
Trials and in the Derivation and Validation Cohorts
HORIZONS-AMI
(n  2,986)
ACUITY
(n  3,153)
Derivation
(n  4,093)
Validation
(n  2,046)
Acute 0.90 0.30 0.60 0.60
Subacute 1.50 1.00 0.90 1.40
Late 1.00 0.70 1.00 1.00
Overall 1 year 3.60 2.00 2.80 2.60
Very late 1.80 NA* NA* NA*
Overall 3 year 5.00 NA* NA* NA*
Values are %. *Maximum follow-up duration in ACUITY was 1 year.
ACUITY  Acute Catheterization and Urgent Intervention Triage Strategy; HORIZONS-AMI 
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction; NA
not available; ST stent thrombosis.after primary PCI in the HORIZONS-AMI trial, and atotal of 3,153 patients who underwent PCI with stent
placement in the ACUITY trial with complete datasets
were included in this patient-pooled analysis (total cohort
n  6,139). Most patients were treated with at least 1
drug-eluting stent (n  5,000, n  81.4%). The cohort was
then randomly split in a 2:1 fashion into development (n 
,093) and validation (n  2,046) cohorts. There were no
ifferences in baseline clinical, angiographic, and procedural
haracteristics or in clinical outcomes between patients in
he development and validation cohorts. The incidence of
T events in the individual trials and the development and
alidation cohorts according to the Academic Research
onsortium’s timing definitions is shown in Table 1.
Development dataset. Variables included in the risk score
and their hazard ratios are shown in Table 2. Independent
predictors of ST at 1-year follow-up were type of ACS
(STEMI, non–ST-segment elevation acute coronary syn-
drome [NSTE-ACS] with ST-segment deviation, or
NSTE-ACS without ST-segment changes), current smok-
ing, insulin-dependent diabetes mellitus, prior PCI, base-
line platelet count, absence of early (pre-PCI) anticoagulant
therapy, ulceration or aneurysm of target lesion, baseline
TIMI flow grade 0/1, final TIMI flow grade 3, and
number of treated vessels.
Table 3 shows the corresponding integer assignments
and calculation of the risk score. Each variable was
assigned a 1 to 4 score according to the strength of
the statistical association. The distribution of the integer
risk score and consequent probability of ST at 1 year is
shown in Figures 1A and 1B (p value for trend 0.0001).
The C-statistic for the risk score was 0.67 in the develop-
ment cohort. From observation of these data, 3 categories of
ST risk might arbitrarily be defined: risk scores 1 to 6 were
considered low risk, 7 to 9 intermediate risk, and 10 or
greater high risk for ST. Rates of ST in low-, intermediate-,
Table 2. HR of Independent Predictors of Definite/Probable ST in the
Development Cohort
Variables HR 95% CI p Value
Baseline platelet count 1.00 1.00–1.01 0.005
Current smoking 1.64 1.11–2.43 0.01
Insulin-treated diabetes mellitus 2.41 1.34–4.36 0.004
Final TIMI ﬂow grade 3 0.49 0.29–0.83 0.008
History of PCI 1.70 1.06–2.72 0.03
Early (pre-PCI) heparin therapy* 0.63 0.43–0.93 0.02
Aneurysm or ulceration 2.18 1.21–3.93 0.01
Baseline TIMI ﬂow grade 0/1 2.36 1.51–3.70 0.0002
Number of vessels treated 1.75 1.05–2.91 0.03
Type of acute coronary syndrome 1.39 1.08–1.80 0.01
*Includes parenteral heparin or lowmolecular weight heparin.
CI confidence interval; HR hazard ratio; PCI percutaneous coronary intervention; STstent thrombosis; TIMI Thrombolysis In Myocardial Infarction.
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1100and high-risk groups are shown in Figures 1C and 1D (p
value for trend 0.0001).
Independent predictors and corresponding risk models for
definite/probable early (0 to 30 days) and late (1 month to 1
year) ST are shown in Tables 4 and 5, respectively. The
-statistics in the development cohort for the early ST model
nd the late ST model were 0.76 and 0.76, respectively.
Score validation. Figures 2A and 2B show the distribution
of the integer risk score and consequent probability of
Table 3. Integer-Based Risk Score for 1-Year Definite
Variable Integer Assi
Type of ACS NSTE-ACS
w/o ST-segment
changes: 1
Current smoking Yes: 1
Insulin-treated diabetes mellitus Yes: 2
History of PCI Yes: 1
Baseline platelet count, K/l 250: 0
Absence of early (pre-PCI) heparin* Yes: 1
Aneurysm or ulceration Yes: 2
Baseline TIMI ﬂow grade 0/1 Yes: 1
Final TIMI ﬂow grade 3 Yes: 1
Number of vessels treated 1: 0
ST risk score:
*Includes parenteral heparin or lowmolecular weight heparin.
ACSacute coronary syndrome (s);NSTE-ACSNon–ST-segmente
infarction; other abbreviations as in Tables 1 and 2.
Figure 1. Distribution of the Integer Risk Score and Consequent Probabilit
Distribution of the integer risk score (A); incidence of deﬁnite/probable stent t
distribution of low-, intermediate-, and high-risk categories (C); and incidence of STdefinite/probable ST at 1 year in the validation cohort. The
C-statistic for the ST risk score model in the validation
cohort was 0.66. Figures 2C and 2D show the distribution
of low-, intermediate-, and high-risk groups, as well as their
corresponding ST rates at 1 year. The ST trends among the
3 risk categories remained significant (p  0.001).
In a secondary analysis, we extended the preceding
validation cohort to also include the data on the extended
follow-up of the HORIZONS-AMI trial (beyond 1 year
able ST in Patients With ACS
t for ST Risk Score Calculation Add to Score
NSTE-ACS
with ST-segment
deviation: 2
STEMI  4
No: 0
No: 0
No: 0
250–400: 1 400: 2
No: 0
No: 0
No: 0
No: 0
2: 1 3: 2
acute coronary syndrome; STEMIST-segmentelevationmyocardial
efinite/Probable ST Within 1 Year in the Derivation Cohort
bosis (ST) by risk score integer (B);/Prob
gnmen
levationy of D
hrom
by risk category (D).
n Table
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1101and until the 3-year study end) to also include a very late ST
assessment. The ST rates in the low-, intermediate-, and
high-risk categories were 2.52%, 4.70%, and 12.68% (p for
trend 0.0001), respectively, and the C-statistic was 0.69
(Fig. 3). The performance of the ST risk score was similar
when it was validated to exclusively predict very late ST in
the HORIZONS-AMI trial; ST rates were 1.08%, 1.92%,
and 2.75% in the low-, intermediate-, and high-risk groups,
respectively (p  0.04). The C-statistics in the validation
cohort for the early ST model and the late ST model were
0.67 and 0.66, respectively.
Discussion
The current analysis in a patient-pooled dataset of 2 large
randomized clinical trials that span the spectrum of ACS
resulted in the development and validation of a convenient
Table 4. Early ST (0 to 30 Days) Predictors and Risk
Ear
Outcome N Events, n
Deﬁnite/probable ST: 30 days 2,997 69
Baseline platelet count, K/l 25
History of IDDM Ye
Final TIMI ﬂow grade 3 vs. 0/1/2 Ye
Early anticoagulant therapy Ye
Aneurysm or ulceration Ye
Baseline TIMI ﬂow grade 0/1 vs. 2/3 Ye
Number of vessels treated
IDDM insulin-dependent diabetes mellitus; other abbreviations as i
Table 5. Late Stent Thrombosis (1 Month to 1 Year)
Late Stent Thr
Outcome N Events,
Deﬁnite/probable ST: 30 days 2,928 58
Current smoking
History of PCI
STEMI vs. NSTE-ACSAbbreviations as in Tables 1, 2, and 3.integer-based risk score consisting of 10 readily available
variables. We believe that the development and initial
validation of this ST risk score can be a useful tool for both
clinical practice and future clinical investigation (future
analyses of trials or registries), as it can be a simple way to
risk stratify patients immediately following a procedure.
The risk score could also be used in the informed consent
process to better inform patients of their individual risk of
ST (16).
In our analyses, we found that most patients were in the
low-risk categories (Figs. 1C and 2C). This is in accordance
with the rarity of ST events and with the great difficulties
that smaller datasets with less prolonged follow-up would
have had to perform such an analysis. In addition, we
documented highly statistically significant incremental
ST rates with increasing risk score integer values in both
e (Development Cohort)
0–30 Days) Predictors and Risk Score
Predictor HR (95% CI) p Value
e platelet count 1.00 (1.00–1.01)] 0.002
of IDDM 2.36 (1.25–4.46) 0.008
IMI ﬂow grade 3 vs. 0/1/2 0.43 (0.24–0.75) 0.003
nticoagulant therapy 0.61 (0.39–0.95) 0.03
sm or ulceration 2.37 (1.25–4.50) 0.009
e TIMI ﬂow grade 0/1 vs. 2/3 3.43 (2.08–5.66) 0.0001
r of vessels treated 1.80 (1.05–3.08) 0.03
Score Assignment
250–400: 1 400: 2
No: 0
No: 2
No: 1
No: 0
No: 0
3: 2
s 1 and 2.
ctors and Risk Score (Development Cohort)
is (1 Month to 1 Year) Predictors and Risk Score
Predictor HR (95% CI) p Value
History of PCI 2.84 (1.17–6.89) 0.02
STEMI vs. NSTE-ACS 3.72 (1.46–9.45) 0.006
Current smoking 4.00 (1.66–9.64) 0.002
Score Assignment
3 No: 0
2 No: 0
CS: 0 STEMI: 3Scor
ly ST (
Baselin
History
Final T
Early a
Aneury
Baselin
Numbe
0:0
s:2
s:0
s:0
s:2
s:2
2:1Predi
ombos
n
Yes: 
Yes: 
NSTE-A
of ST
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1102the development and validation datasets. These trends
paralleled each other in the derivation and validation
cohorts.
Prior reports have suggested that predictors may differ for
early (including acute and subacute) ST compared with
late/very late ST (14,17). Late and very late ST may have a
restenotic or neoatherosclerotic origin, whereas early ST
may be more device- or pharmacology-related. Nonetheless,
the present risk score was able to similarly predict the
occurrence of ST not only within the first year, but also,
including very late ST events.
The variables of the proposed risk score can be subcate-
gorized into clinical and laboratory, pharmacological, and
angiographic variables. Clinical variables include: type of
ACS, prior studies have suggested higher ST rates in
STEMI than in NSTE-ACS (7,14), moreover, the current
investigation reported higher ST rates after NSTE-ACS
with ST-segment deviation1 mm compared with NSTE-
ACS without ST-segment deviation; insulin-treated diabe-
tes mellitus (previously described as a powerful predictor of
subacute, late, and very late ST) (6,14); previous PCI, which
might indicate prior stent placement and could also signify
an index ACS because of ST of a previously implanted
stent; current smoking, which has been associated with ST
Figure 2. Distribution of the Integer Risk Score and Consequent Probabilit
Distribution of the integer risk score (A); incidence of deﬁnite/probable stent t
distribution of low-, intermediate-, and high-risk categories (C); and incidencein multiple prior studies (6,14). Additionally, the laboratoryvalue of thrombocytosis has been reported to be associated
with ST in an earlier analysis in the HORIZONS-AMI
trial (14).
We previously reported a protective effect of pre-
randomization use of heparin in the HORIZONS-AMI
trial (14). This important pharmacological variable was
generalized as early (pre-PCI) administration of anticoagu-
lant therapy to facilitate the clinical applicability of the
current risk score. To be more specific, we mean any early
use of a readily available parenteral heparin (either unfrac-
tionated or low molecular weight) therapy in the emergency
department, ambulance, or medical floor well before the
start of the PCI procedure. With respect to early use of
GPI, the ACUITY timing substudy had already shown no
difference with respect to clinical outcomes (including ST)
of early versus during-PCI administration of these agents
(18,19). With respect to early clopidogrel administration, an
earlier report from the same trial found no major difference
in outcomes with earlier administration as long as clopi-
dogrel was administered before the procedure (20). Future
investigation of different datasets that may include other
potent antiplatelet agents administered at different times
before PCI may be able to further identify whether such
efinite/Probable ST Within 1 Year in the Validation Cohort
osis (ST) by risk score integer (B);
by risk category (D).y of D
hrombpractices may be protective of ST (21–23). The present
Infarc
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1103study did not assess the discontinuation of antiplatelet
therapy, which is a known important modifier of ST risk
during the follow-up time (3), because we aimed to derive a
risk score for ST based on information available solely at the
time of stent implantation procedure.
Angiographic variables of this risk score largely reflect the
thrombotic load. A baseline TIMI grade flow of 0 or 1 at
the target lesion of an ACS patient signifies an occlusive
thrombus at the time of PCI, and a final TIMI grade flow
3 during an ACS generally indicates distal embolization
and microvascular impairment from microthrombi and va-
soactive substances. Aneurysms or ulcerations at the target
lesion site have also been used as indicators of thrombus
(15). All of these parameters have also been associated with
unfavorable outcomes in part due to possible misinterpre-
tation of the true vessel size during stent implantation,
possibly leading to malapposition (24,25). The number of
treated vessels during the index PCI procedure during an
ACS was also an important risk factor of ST. Finally,
thrombus extraction before STEMI angioplasty has been
associated with improved outcomes in a single large study
Figure 3. Distribution of the Integer Risk Score and Consequent Probabilit
Validation Cohort (Dataset) Enriched With 3-Year Follow-Up Data in HORIZ
Distribution of the integer risk score (A); incidence of deﬁnite/probable stent t
high-risk categories (C); and incidence of ST by risk category (D). ACUITY  Ac
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial(26). This study was completed after HORIZONS-AMIenrollment; the very low rate of aspiration thrombectomy in
HORIZONS-AMI precluded the meaningful assessment
of this variable in the present risk score.
We did not include the type of stent used, because no
major difference in ST has been found between bare-
metal stents and first-generation drug-eluting stent types
within the trials we analyzed (19). This also has been
reported by other research groups (27). Whether newer
generation drug-eluting stents or future bioabsorbable or
other stent designs may affect the incidence of ST,
particularly very late ST, remains a question for further
investigation. Recent evidence indeed suggests a suppres-
sion of ST with a widely studied second-generation
drug-eluting stent (27).
The present risk score was developed and validated in
patients with ACS; therefore, it may not be applicable to the
large population of patients with elective or nonurgent PCI.
It is also possible that other variables, such as multilesion/
multistent PCI, SYNTAX (Synergy Between PCI With
Taxus and Cardiac Surgery) score (28), bifurcation anat-
omy, and lesion or stent length may be preferable for
efinite/Probable ST Within 1 Year in the
MI
osis (ST) by risk score integer (B); distribution of low-, intermediate-, and
atheterization and Urgent Intervention Triage Strategy; HORIZONS-AMI 
tion.y of D
ONS-A
hromb
ute Cinclusion in an ST risk score for use in an elective/nonurgent
11
1
1
1
1
1
1
1
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1104PCI population. By contrast, the present risk score could
also be validated in an elective/nonurgent PCI population
with simple exclusion of the nonapplicable variables or in
combination with an angiographic burden/jeopardy score
(either for the entire coronary anatomy or of the target areas
of the index PCI/stenting).
Risk factors associated with ST are multifactorial; in this
respect, the present study has not been able to incorporate
intravascular ultrasound imaging, genotyping information,
and thienopyridine nonadherence or resistance data. Al-
though each of these categories of risk factors has been
indeed implicated in ST, very rarely are they taken under
account at the time of PCI/stenting, especially in the urgent
ACS setting. Very low rate of intravascular ultrasound use,
almost nonexistent testing for genotypes and very scarce
testing for platelet function have been documented in
worldwide clinical practice for a variety of reasons. Even
from a statistical point of view, the application of too many
variables in the prediction model for such a rare clinical
event would weaken the analysis methodology by overfitting
the model. However, the aim of the current study was to
provide a simple risk score that can be used to determine the
risk of ST in ACS patients at the end of the procedure.
Therefore, we opted to focus on a practical approach to
assessing ST risk with use of readily available at time of PCI
clinical and angiographic variables. Based on this risk
assessment tool, practicing physicians could then triage the
use of these additional risk factors in accordance to future
studies and treatment guidelines.
Study limitations. This analysis of ST risk estimation was
based on 2 clinical trials: 1 in patients with STEMI; 1 in
patients with unstable angina or non-STEMI. In these
trials, no data were collected on deployment pressure and
CYP2C19 alleles. In addition, thrombus extraction before
STEMI angioplasty has been associated with improved
outcomes (26); only a small proportion of patients in the
ACUITY and HORIZONS-AMI trials received this ad-
junctive treatment that limited our ability to investigate a
potential protective effect. As HORIZONS-AMI and
ACUITY were randomized clinical trials with specific
inclusion and exclusion criteria, further validation of this
risk score in different ACS trials and registries conducted by
other research groups would be desirable. Finally, further
validation in patients undergoing an elective or nonurgent
PCI with stent implantation would be ideally done within
other large trials or registries conducted in appropriately
defined patient populations.
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